Diagnosis of malignant cardiac disease by endomyocardial biopsy

T. R. Flipse, H. D. Tazelaar, David Holmes

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Among oncology patients, endomyocardial biopsy has been used primarily for the evaluation of anthracycline cardiotoxicity. In addition, however, endomyocardial biopsy may be useful for the detection of malignant cardiac neoplasms. Between 1982 and 1989, metastatic involvement of the heart was diagnosed by endomyocardial biopsy in seven patients at our institution. All except one of these patients were older than 50 years of age and had dyspnea as an initial symptom, and all had a known malignant lesion. Results of endomyocardial biopsy confirmed cardiac involvement by a hematologic malignant lesion in four patients and metastatic melanoma in two patients. In one patient, who had a history of breast cancer and lymphoma, a metastatic neoplasm of uncertain differentiation was observed. Myocyte damage was evident in endomyocardial biopsy specimens from two of the four patients with hematologic malignant disease. Endomyocardial biopsy was performed to confirm the possibility of metastatic involvement in five patients; in the other two, endomyocardial biopsy was performed to determine whether anthracycline cardiotoxicity was present, and metastatic involvement was unanticipated.

Original languageEnglish (US)
Pages (from-to)1415-1422
Number of pages8
JournalMayo Clinic Proceedings
Volume65
Issue number11
StatePublished - 1990
Externally publishedYes

Fingerprint

Heart Diseases
Biopsy
Anthracyclines
Heart Neoplasms
Hematologic Diseases
Dyspnea
Muscle Cells
Melanoma
Lymphoma
Breast Neoplasms
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Diagnosis of malignant cardiac disease by endomyocardial biopsy. / Flipse, T. R.; Tazelaar, H. D.; Holmes, David.

In: Mayo Clinic Proceedings, Vol. 65, No. 11, 1990, p. 1415-1422.

Research output: Contribution to journalArticle

Flipse, TR, Tazelaar, HD & Holmes, D 1990, 'Diagnosis of malignant cardiac disease by endomyocardial biopsy', Mayo Clinic Proceedings, vol. 65, no. 11, pp. 1415-1422.
Flipse, T. R. ; Tazelaar, H. D. ; Holmes, David. / Diagnosis of malignant cardiac disease by endomyocardial biopsy. In: Mayo Clinic Proceedings. 1990 ; Vol. 65, No. 11. pp. 1415-1422.
@article{872324af785f49af9e91e674bca52d82,
title = "Diagnosis of malignant cardiac disease by endomyocardial biopsy",
abstract = "Among oncology patients, endomyocardial biopsy has been used primarily for the evaluation of anthracycline cardiotoxicity. In addition, however, endomyocardial biopsy may be useful for the detection of malignant cardiac neoplasms. Between 1982 and 1989, metastatic involvement of the heart was diagnosed by endomyocardial biopsy in seven patients at our institution. All except one of these patients were older than 50 years of age and had dyspnea as an initial symptom, and all had a known malignant lesion. Results of endomyocardial biopsy confirmed cardiac involvement by a hematologic malignant lesion in four patients and metastatic melanoma in two patients. In one patient, who had a history of breast cancer and lymphoma, a metastatic neoplasm of uncertain differentiation was observed. Myocyte damage was evident in endomyocardial biopsy specimens from two of the four patients with hematologic malignant disease. Endomyocardial biopsy was performed to confirm the possibility of metastatic involvement in five patients; in the other two, endomyocardial biopsy was performed to determine whether anthracycline cardiotoxicity was present, and metastatic involvement was unanticipated.",
author = "Flipse, {T. R.} and Tazelaar, {H. D.} and David Holmes",
year = "1990",
language = "English (US)",
volume = "65",
pages = "1415--1422",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Diagnosis of malignant cardiac disease by endomyocardial biopsy

AU - Flipse, T. R.

AU - Tazelaar, H. D.

AU - Holmes, David

PY - 1990

Y1 - 1990

N2 - Among oncology patients, endomyocardial biopsy has been used primarily for the evaluation of anthracycline cardiotoxicity. In addition, however, endomyocardial biopsy may be useful for the detection of malignant cardiac neoplasms. Between 1982 and 1989, metastatic involvement of the heart was diagnosed by endomyocardial biopsy in seven patients at our institution. All except one of these patients were older than 50 years of age and had dyspnea as an initial symptom, and all had a known malignant lesion. Results of endomyocardial biopsy confirmed cardiac involvement by a hematologic malignant lesion in four patients and metastatic melanoma in two patients. In one patient, who had a history of breast cancer and lymphoma, a metastatic neoplasm of uncertain differentiation was observed. Myocyte damage was evident in endomyocardial biopsy specimens from two of the four patients with hematologic malignant disease. Endomyocardial biopsy was performed to confirm the possibility of metastatic involvement in five patients; in the other two, endomyocardial biopsy was performed to determine whether anthracycline cardiotoxicity was present, and metastatic involvement was unanticipated.

AB - Among oncology patients, endomyocardial biopsy has been used primarily for the evaluation of anthracycline cardiotoxicity. In addition, however, endomyocardial biopsy may be useful for the detection of malignant cardiac neoplasms. Between 1982 and 1989, metastatic involvement of the heart was diagnosed by endomyocardial biopsy in seven patients at our institution. All except one of these patients were older than 50 years of age and had dyspnea as an initial symptom, and all had a known malignant lesion. Results of endomyocardial biopsy confirmed cardiac involvement by a hematologic malignant lesion in four patients and metastatic melanoma in two patients. In one patient, who had a history of breast cancer and lymphoma, a metastatic neoplasm of uncertain differentiation was observed. Myocyte damage was evident in endomyocardial biopsy specimens from two of the four patients with hematologic malignant disease. Endomyocardial biopsy was performed to confirm the possibility of metastatic involvement in five patients; in the other two, endomyocardial biopsy was performed to determine whether anthracycline cardiotoxicity was present, and metastatic involvement was unanticipated.

UR - http://www.scopus.com/inward/record.url?scp=0025202371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025202371&partnerID=8YFLogxK

M3 - Article

VL - 65

SP - 1415

EP - 1422

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -